Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva's anti-IL-15 candidate, TEV-'408 TE ...

YANCHENG, JIANGSU, CHILE, January 7, 2026 /EINPresswire.com/ -- In the face of increasingly demanding industrial and ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 ...

The 2025 USA Rice Outlook Conference featured a discussion on the OBBBA, highlighting its impact on conservation and crop ...

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads today ...

Reckitt Benckiser Group plc (RBGLY) earns a hold rating due to its strong emerging markets exposure and ongoing portfolio ...

There are institutions whose decline happens so gradually that, one day, the public simply wakes up to a painful conclusion: ...

Prior to starting his own business, Mark served as the Technical Editor on EC&M for six years, worked three years in nuclear ...

Discover the top 3 undervalued Hotels, Restaurants & Leisure stocks for Wednesday, January 07 based on AAII’s Stock Grades.

MIchaelAaron Flicker is the co-author of "Hacking The Human Mind: The Behavioral Science Secrets Behind 17 of the World's ...

Giving glove materials a verifiable “memory” to support safe recovery, traceability, and circular reuse NEW YORK, NY / ACCESS Newswire / December 31, 2025 / SMX (Security Matters) PLC (NASDAQ:SMX; ...